Purple Biotech (PPBT) Total Non-Current Liabilities (2016 - 2026)
Purple Biotech's (PPBT) quarterly Total Non-Current Liabilities came in at $160000.0 in Q1 2026, up 14.29% year-on-year from $140000.0 in Q1 2025, and little changed on a QoQ basis from $160000.0 in Q4 2025.
Purple Biotech (PPBT) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 11 years of Total Non-Current Liabilities data on file, last reported at $160000.0 in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 14.29% year-over-year to $160000.0 in Q1 2026; TTM through Mar 2026 was $160000.0, a 14.29% increase from a year earlier, with the FY2025 full-year figure at $160000.0, up 14.29% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $160000.0, roughly flat from $160000.0 in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for PPBT reached as high as $787000.0 in Q1 2022 and fell as low as $140000.0 in Q4 2024.
- Historically, Total Non-Current Liabilities has averaged $321705.9 across 5 years, with a median of $262000.0 in 2024.
- Across the five-year window, Total Non-Current Liabilities slumped 53.95% in 2024 and advanced 14.29% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $466000.0 in 2022, then sank by 34.76% to $304000.0 in 2023, then slumped by 53.95% to $140000.0 in 2024, then gained by 14.29% to $160000.0 in 2025, then changed by 0.0% to $160000.0 in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $160000.0 in Q1 2026, $160000.0 in Q4 2025, and $189000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Purple Biotech | 1.33 Bn | 1.33 Bn | - | 160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160,000.00 |
| Dec 31, 2025 | 160,000.00 |
| Sep 30, 2025 | 189,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 179,000.00 |
| Jun 30, 2024 | 220,000.00 |
| Mar 31, 2024 | 262,000.00 |
| Dec 31, 2023 | 304,000.00 |
| Sep 30, 2023 | 333,000.00 |
| Jun 30, 2023 | 378,000.00 |
| Mar 31, 2023 | 419,000.00 |
| Dec 31, 2022 | 466,000.00 |
| Sep 30, 2022 | 501,000.00 |
| Jun 30, 2022 | 691,000.00 |
| Mar 31, 2022 | 787,000.00 |
| Dec 31, 2021 | 842,000.00 |
| Sep 30, 2021 | 828,000.00 |
| Jun 30, 2021 | 870,000.00 |